EZH2 and prostate carcinoma: Elevated expression of EZH2 has been described in a broad range of cancer types, such as prostate cancer [28], lung cancer [29], breast cancer [30], liver cancer [14] and colon cancer [31], and has been correlated with aggressive clinical manifestations.